RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Minerva Neurosciences Stock

Minerva Neurosciences P/S 2024

Minerva Neurosciences P/S

0.92

Ticker

NERV

ISIN

US6033801068

WKN

A1171S

As of Sep 29, 2024, Minerva Neurosciences's P/S ratio stood at 0.92, a 0% change from the 0 P/S ratio recorded in the previous year.

The Minerva Neurosciences P/S history

Minerva Neurosciences Aktienanalyse

What does Minerva Neurosciences do?

Minerva Neurosciences was founded in 2007 and is a biopharmaceutical company focused on developing therapies for various psychiatric and neurological disorders. The company's business model is based on identifying promising molecules and developing them clinically until they are approved by health authorities. Minerva works closely with academic institutions and other partners to expand its pipeline of potential products. The company is focused on developing therapies for disorders such as schizophrenia, depression, sleep disorders, Parkinson's, and Alzheimer's. Minerva Neurosciences' main products are the antipsychotic MIN-101, targeting the treatment of schizophrenia, and the antidepressant MIN-117, developed for the treatment of depression. Both products are currently in clinical development and have the potential to offer new treatment options for patients. Furthermore, Minerva Neurosciences has entered into exclusive licensing agreements with other companies to develop innovative therapies for rare diseases. One of these products is the medication Roluperidone, which can be used for schizophrenic disorders. Minerva Neurosciences is divided into three business segments: Minerva Neurosciences Inc, Minerva Manufacturing Inc, and Minerva Therapeutics Inc. Minerva Manufacturing has its own research and development department and specializes in manufacturing clinical trial products. Minerva Therapeutics is a subsidiary focused on developing gene therapies for rare diseases. The company aims to improve the quality of life for patients with neurological and psychiatric disorders. Minerva Neurosciences pursues a strategy of collaborating with external partners and academic institutions to foster innovation and develop new therapies. Overall, Minerva Neurosciences has the potential to play a significant role in the treatment of central nervous system disorders and improve the health and well-being of millions of people worldwide. Minerva Neurosciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Minerva Neurosciences's P/S Ratio

Minerva Neurosciences's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Minerva Neurosciences's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Minerva Neurosciences's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Minerva Neurosciences’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Minerva Neurosciences stock

What is the price-to-earnings ratio of Minerva Neurosciences?

The price-earnings ratio of Minerva Neurosciences is currently 0.92.

How has the price-earnings ratio of Minerva Neurosciences changed compared to last year?

The price-to-earnings ratio of Minerva Neurosciences has increased by 0% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Minerva Neurosciences high compared to other companies?

Yes, the price-to-earnings ratio of Minerva Neurosciences is high compared to other companies.

How does an increase in the price-earnings ratio of Minerva Neurosciences affect the company?

An increase in the price-earnings ratio of Minerva Neurosciences would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Minerva Neurosciences affect the company?

A decrease in the price-earnings ratio of Minerva Neurosciences would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Minerva Neurosciences?

Some factors that influence the price-earnings ratio of Minerva Neurosciences are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Minerva Neurosciences pay?

Over the past 12 months, Minerva Neurosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Minerva Neurosciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Minerva Neurosciences?

The current dividend yield of Minerva Neurosciences is .

When does Minerva Neurosciences pay dividends?

Minerva Neurosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Minerva Neurosciences?

Minerva Neurosciences paid dividends every year for the past 0 years.

What is the dividend of Minerva Neurosciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Minerva Neurosciences located?

Minerva Neurosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Minerva Neurosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Minerva Neurosciences from 9/29/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/29/2024.

When did Minerva Neurosciences pay the last dividend?

The last dividend was paid out on 9/29/2024.

What was the dividend of Minerva Neurosciences in the year 2023?

In the year 2023, Minerva Neurosciences distributed 0 USD as dividends.

In which currency does Minerva Neurosciences pay out the dividend?

The dividends of Minerva Neurosciences are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Minerva Neurosciences stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Minerva Neurosciences

Our stock analysis for Minerva Neurosciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Minerva Neurosciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.